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Abstract
Background: We previously developed in vitro immunization based on a fusion protein containing the transcriptional
transactivator (Tat) of human immunodeficiency virus and a double domain, called ZZ, derived from protein A of
Staphylococcus aureus. In this approach, naïve human peripheral blood mononuclear cells (PBMCs) trigger a specific IgM
antibody (Ab) response in the presence of ZZTat. In the present study, we attempted to raise a specific IgG Ab response.
Results: We found that PBMCs incubated with ZZTat and a mixture containing anti-CD40, IL4 and IL21 secrete anti-Tat
IgG Abs in their supernatants, indicating that the cytokine cocktail provides an isotypic switch. Then, we deciphered the
Tat determinant involved in the phenomenon and found that it is located in the region 22–57 and that, within this
region, the cysteine-rich domain and the basic residues play a crucial role. Finally, we prepared a fusion protein
containing a fragment derived from the NY-ESO-1 cancer/testis antigen (Ag) and showed that PBMCs incubated with
ZZfNY-ESO-1Tat trigger a specific anti-fNY-ESO-1 IgG Ab response, which demonstrates the possibility of transferring
immunizing ability to an Ag unrelated to Tat.
Conclusion: Our ZZTat-based in vitro immunization approach that offers the possibility to raise an IgG Ab response
against NY-ESO-1 might represent a valuable first stage for the generation of fully human IgG specific Abs.
Keywords: Human antibodies, In vitro immunization, Transcriptional transactivator, ZZ domain
Background
Monoclonal antibodies (mAbs) are the fastest growing
class of therapeutic agents [1]. Mouse mAbs were first
used for therapy in humans [2]. However, their xenogen-
eic sequences make them prone to elicit immunogenic
responses, in particular human anti-mouse antibodies
that can reduce their therapeutic efficacy [3]. This draw-
back led to the development of strategies dedicated to
the preparation of mAb-based therapeutics with a high
content of human sequences [4, 5]. Chimerization and
humanization approaches have addressed this issue with
substantial efficiency since, currently, they account for
22 of the 30 mAbs approved for clinical applications [6].
However, some patients still develop anti-Ab responses
against these engineered molecules [7]. Therefore, to
address this immunogenic drawback more efficiently,
numerous studies have been aimed at generating Ab-
based molecules containing fully-human sequences [8].
Approaches have been developed using phage display
methods [9, 10] or transgenic mice containing human
immunoglobulin genes [11]. Other strategies are based
on the isolation of human B-lymphocytes from human
donors [12, 13]. The latter approaches, which are of
proven efficiency with immune donors [12], are more
difficult to implement when donors are naïve for the tar-
get Ag, due to the difficulty of triggering stimulation of
specific B-lymphocytes in vitro. Several research groups
have developed various in vitro immunization proce-
dures for the preparation of specific immortalized
human B-lymphocytes using various fusion partners [14,
15] or Epstein-Barr virus [16–18]. However, these tech-
niques have a poor yield and reproducibility [19–21].
Furthermore, the protocols reported are complex since
they require several steps for depletion or enrichment
of various sub-populations [15, 22].
We recently considered the possibility of improving in
vitro immunization and making protocols simpler. As
various cytokines are usually required to achieve efficient
stimulation of naïve lymphocytes by an antigen [23], we
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decided to assess whether an Ag exhibiting several bio-
logical activities related to the triggering of the immune
response, in particular activities that are reminiscent of
those triggered by cytokines and adjuvants, can be used
for in vitro immunization. This Ag is the transcriptional
transactivator of HIV-1, called Tat101, which is a small
protein of 86 to 101 residues [24]. Previous work suggests
that Tat can induce chemotaxis of monocytes [25] and se-
cretion of proinflammatory cytokines [26]. Furthermore,
Tat was proposed to target monocyte-derived dendritic
cells, and to enhance their maturation, function, and Ag-
specific T-cell responses [27]. In addition, this protein can
reprogram immature dendritic cells to express chemoat-
tractants for activated T cells and macrophages [28]. Fur-
thermore, Tat can bind heparan sulfate proteoglycans,
thus increasing the ability of an antigen to stimulate T-
helper cells [29]. Lastly, in mice, Tat is able to raise a
humoral immune response in the absence of adjuvant [30]
and the determinant controlling this unusual property can
be used to confer the adjuvant-free characteristic on an-
other Ag [31].
To assess whether Tat is able to trigger a humoral im-
mune response in vitro and if we can transfer this ability
to other Ags, we used a genetic system that allows the
expression of one or more Ags in tandem [32]. In this
system, the Ags are fused to a double Ig-binding domain,
called ZZ, which is derived from protein A of Staphylo-
coccus aureus [33]. In a previous study, we prepared a
ZZ-fusion protein, named ZZTat101, containing the
transcriptional transactivator of HIV-1 and showed that
i) ZZTat101 is able to trigger the production of
anti-Tat101 antibodies by PBMCs in the absence of cyto-
kines, indicating that the fusion protein behaves as a sur-
rogate of some of these molecules [34]; ii) the Ab
response does not require a previous depletion of
immunosuppressive cells and is therefore simple to im-
plement; iii) Tat101 can stimulate the in vitro immune
response only when covalently coupled to ZZ and when
the Tat cysteines are present in the fusion protein, dem-
onstrating that these residues play a crucial role in the
phenomenon; iv) the covalent coupling of a hapten to
ZZTat101 enables PBMCs to trigger an anti-haptenic Ab
response, indicating that the ability to trigger a humoral
immune response in vitro can be conferred on another
Ag. However, during these experiments, we only found
specific Abs of the IgM class, indicating that ZZTat is
able to initiate the signals required to trigger a primary
immune response, but failed to induce the isotypic
switch.
In the present study, we addressed several issues. Firstly,
can we find an optimized in vitro immunization procedure
that enables ZZTat101 to trigger a specific anti-Tat IgG Ab
response? Secondly, what is the frequency of the specific B-
lymphocytes elicited? Thirdly, is it possible to transfer to an
unrelated peptide Ag the ability to trigger an in vitro IgG
Ab response? We assessed this last question using a fusion
protein containing ZZ, Tat101 and a tumor non-haptenic
peptide Ag.
Results
An anti-Tat101 IgG Ab response is triggered in vitro when
PBMCs are incubated with ZZTat101 and a cytokine cock-
tail containing IL-21 + IL-4 + anti-CD40
As we previously observed that the anti-Tat antibodies
secreted by PBMCs after their incubation with ZZTat101
are only of the IgM class [34], we assessed whether
addition of cytokines known to promote an isotype switch
can favor secretion of anti-Tat IgGs. We selected a mixture
containing either IL-21 + IL-4 + CD40L or IL-21 + IL-4 +
anti-CD40 since previous reports showed that IL21 to-
gether with IL4 regulates an isotype switch by human naive
B cells, when cultured with CD40L [35] or anti-CD40 mAb
[36]. To investigate the efficiency of this approach, we incu-
bated PBMCs in the presence or absence of ZZTat101 and/
or cytokine/activator cocktails. Eleven days later, we col-
lected the supernatants (SNs) and examined the presence
of IgG able to bind Tat101-coated plates. As shown in
Fig. 1a, binding is poor with SN from PBMCs incubated in
the absence of Ag and activator. When we compared this
binding with that provided by the other SNs, we did not
find a significant difference for those resulting from the in-
cubation of PBMCS with IL-21/IL-4/CD40L, IL-21/IL-4/
anti-CD40 and ZZTat101, respectively. Therefore, these re-
sults indicated that the cytokine/activator cocktails as well
as ZZTat101 are not able to trigger an anti-Tat IgG re-
sponse when incubated separately. We also found an ab-
sence of statistical difference for SN from PBMCs
incubated with IL-21/IL-4/CD40L and ZZTat101, indicat-
ing that this combination is also inefficient. In contrast, we
observed significantly higher binding with SN from PBMCs
incubated with IL-21/IL-4/anti-CD40/ZZTat101. Further-
more, binding of this latter SN is significantly lower in
plates coated with an antigen unrelated to Tat (not
shown), which suggest that the increased interaction to
Tat-coated plates comes from specific IgGs. Therefore,
altogether these results indicate that an anti-Tat101
isotype switch is caused when PBMCs are incubated
with IL-21/IL-4/anti-CD40 and ZZTat101.
To characterize the specificity of the IgG antibodies
bound to Tat101-coated plates, we assessed binding in
the presence of a fixed amount (10 μg/mL) of three un-
related soluble antigens. We observed that soluble
Tat101 causes significant 70 % inhibition of binding,
whereas neither ovalbumin (OVA) nor lysozyme signifi-
cantly inhibits IgG binding to plates (Fig. 1b). Therefore,
these results indicate that binding to plates is mainly
caused by anti-Tat101-specific IgGs present in the SN of
PBMCs incubated with IL-21/IL-4/anti-CD40/ZZTat101.
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Characterization of the molecular determinant controlling
the ability to raise the specific humoral response
Elicitation of the anti-Tat IgG Ab response requires the covalent
coupling of ZZ and Tat101
To decipher the relative contributions of ZZ and Tat101
to the ability to raise and an IgG Ab response, we incu-
bated PBMCs with the activating cocktail (IL-21/IL-4/
anti-CD40) and various antigenic mixtures. Then we
compared the ability of the SNs resulting from these in-
cubations to bind Tat101-coated plates. For the SNs
from PBMCs respectively incubated with Tat101, ZZ,
and ZZ + Tat101, we found a low optical density that did
not differ significantly from that of the SNs from PBMCs
incubated either without Ag or without Ag and activator
(Fig. 2a). In contrast, we observed a significantly higher
optical density for the SN resulting from the incubation
with ZZTat101/IL-21/IL-4/anti-CD40. Therefore, these
results indicate that i) ZZ and Tat101 cannot trigger the
IgG Ab response when they are used as free molecules,
ii) covalent coupling of Tat101 to ZZ is absolutely re-
quired for the phenomenon.
Elicitation of the anti-Tat IgG Ab response requires the
preservation of the basic region of Tat
As Tat101 contains many lysines, which play a role in
numerous biological activities of the protein [37], we in-
vestigated their role in the in vitro immune response
using a ZZTat101 fusion protein, called ZZTat101Ø, in
which we had previously acetylated the lysine residues
using an excess of acetic anhydride. We incubated PBMCs
in the presence or absence of either ZZTat101Ø or
ZZTat101, and assessed the ability of the SNs to bind
Tat101-coated plates. As shown in Fig. 2b, the optical
density observed with SNs from incubation with
ZZTat101Ø did not differ from that observed with super-
natants from PBMCs incubated in the absence of antigen,
while it was significantly higher with the SNs resulting
from incubation with ZZTat101. Therefore, these results
indicate that acetylation of ZZTat101 abrogates the ability
to trigger the immune response in vitro and that some
lysine residues of the fusion protein contribute to the
phenomenon.
The 22–57 region of Tat suffices to raise the specific
humoral response and its cysteine-rich region controls
the triggering of the IgG response
In order to delineate more thoroughly the Tat region
involved in the ability to raise a humoral immune re-
sponse in vitro, we prepare two ZZTat mutants. The
first, called ZZTat22–57, was selected since i) we
showed that a peptide derived from the 22–57
sequence of Tat is able to raise an adjuvant-free anti-
body response in mice [30], indicating that it can
initiate the immune response, at least in vivo; ii) we
observed that this fusion protein can trigger an anti-
Tat IgM response in vitro [34]. The second, called
ZZTat101C(22–37)S, corresponds to a ZZTat22–57 mu-
tant in which the 7 cysteine residues have been replaced
by serines. We selected this mutant since i) the Tat22–57
region contains a cysteine-rich region (residues 22 to 37)
controlling the capacity to trigger an adjuvant-free
immune response in mice [30]; ii) we observed that this
fusion protein cannot trigger an anti-Tat IgM response
in vitro [34]. We incubated ZZTat101, ZZTat22–57 and
ZZTat101C(22–37)S in the presence of PBMCs, collected the
Fig. 1 a An anti-Tat IgG Ab response is raised in vitro when PBMCs are
incubated with ZZTat101 and a cytokine/activator cocktail. PBMCs (5 ×
105 cells per well) were incubated with or without CD40L/IL-4/IL-21,
anti-CD40/IL-4/IL-21, ZZTat101, ZZTat101 + CD40L/IL-4/IL-21,
ZZTat101 + anti-CD40/IL-4/IL-21, respectively. Then, supernatants
were collected and added to Tat101-coated plates. After overnight
incubation, a peroxidase-conjugated anti-human IgG was added
and enzymatic activity was determined using ABTS as substrate.
b The anti-Tat IgG Ab response is specific to Tat101. Supernatants
from PBMCs incubated with ZZTat101 + anti-CD40/IL-4/IL-21 were
mixed with either a dilution buffer or a fixed amount (10 μg/mL)
of three different Ags (Tat101, ovalbumin, lysozyme) and incubated
in Tat101-coated plates. Presence of anti-Tat IgG was assessed as in
A (**: p < 0.01; ***: p < 0.001)
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SNs and assessed their ability to bind to Tat101-coated
plates. For the SNs from ZZTat101 and ZZTat22–57 incu-
bations, we found close optical density values that are sig-
nificantly higher than that of the SNs from PBMCs
incubated in the absence of Ag, indicating that the region
22–57 of Tat101 suffices to trigger an in vitro immune re-
sponse (Fig. 3). In contrast, when we compared the SN
from ZZTat101C(22–37)S incubation with the SNs from
PBMCs incubated in the absence of Ag, we did not find a
significant difference of optical density, indicating that the
cysteine-rich region of Tat101 controls the triggering of
the IgG immune response.
Determination of the frequency of Tat101-specific
IgG-secreting B-lymphocytes
In order to determine the number of Tat101-specific IgG-
secreting B-lymphocytes during the in vitro immunization
experiments, we assessed the number of Tat-specific SFCs
in PBMCs incubated for different times with IL-21/IL-4/
anti-CD40 in the presence or absence of ZZTat. In these
experiments, the last day of incubation we transferred the
PBMC samples from culture plates to ELISPOT plates
previously coated with Tat101 and measured the number
of IgG anti-Tat SFCs after an additional 24-h incubation at
37 °C. As shown in Fig. 4, a number of spots ranging from
25 to 50 was observed in samples from PBMCs incubated
only with IL-21/IL-4/anti-CD40. This amount is signifi-
cantly higher than that found in samples from control
PBMCs incubated in the absence of the activating cocktail,
indicating that the cocktail induces some B-lymphocytes
to secrete IgGs endowed with the ability to bind Tat-
coated plates. This behavior could be due to non-specific
interactions or to the presence of B-lymphocytes secreting
polyreactive IgGs of low affinity that are detected due to
the high sensitivity of the ELISPOT as compared to the
Fig. 3 The 22–57 region of Tat suffices to raise an IgG response and
preservation of the cysteine residues is absolutely required for the
phenomenon. PBMCs were incubated for seven days with or without
anti-CD40/IL-4/IL-21, ZZTat101 + anti-CD40/IL-4/IL-21, ZZTat22-57 + anti-
CD40/IL-4/IL-21, ZZTat22-57C(22–37)S + anti-CD40/IL-4/IL-21, respectively.
Then, supernatants were collected and added to Tat101-coated plates.
Presence of anti-Tat IgG was subsequently assessed as described
in Fig. 1a
Fig. 2 a The covalent coupling of Tat101 to ZZ is absolutely required to
trigger an anti-Tat IgG Ab response. PBMCs were incubated with
or without anti-CD40/IL-4/IL-21, ZZTat101, ZZTat101 + anti-CD40/
IL-4/IL-21, ZZ + anti-CD40/IL-4/IL-21, ZZ + Tat101 + anti-CD40/IL-4/
IL-21, Tat101 + anti-CD40/IL-4/IL-21, respectively. Then, supernatants
were collected and added to Tat101-coated plates. Presence of anti-Tat
IgG was assessed as in Fig. 1a. b The anti-Tat IgG response requires
preservation of the Tat lysines. PBMCs were incubated with or without
anti-CD40/IL-4/IL-21, ZZTat101 + anti-CD40/IL-4/IL-21, ZZTat101ϕ + anti-
CD40/IL-4/IL-21, respectively. Presence of anti-Tat IgG was assessed in
supernatants as in Fig. 1a (*: p < 0.05)
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ELISA methodology. Finally, when we compared PBMCs
incubated only with IL-21/IL-4/anti-CD40 with PBMCs
incubated with IL-21/IL-4/anti-CD40 and ZZTat101, we
found that the latter cells contained a significant 2.5- to 6-
fold higher amount of SFCs, indicating that the activating
mixture triggers a specific B-lymphocyte response that
peaks after 11 days of in vitro immunization.
The ZZ-Tat-based approach can confer on fNY-ESO-1 the
ability to trigger an IgG Ab response in vitro
Since the ZZ-fusion system allows the production of one
or more antigens in tandem [32], we decided to build a
ZZ-fusion protein containing both Tat22-57 and a hu-
man tumor antigen. We selected NY-ESO-1, a protein
which is expressed in a wide range of cancers and whose
normal tissue expression is generally restricted to testis
[38]. However, as a previous report suggested that the
whole NY-ESO-1 protein is poorly expressed in E. coli
[39], we decided to use a NY-ESO-1 fragment of 44 resi-
dues that we called fNY-ESO-1. We used peptide chem-
istry to synthesize the free fragment and molecular
biology to produce the fusion protein, called ZZfNY-
ESO-1Tat22-57. Then, in in vitro immunization experi-
ments we assessed whether the stimulating capacity of
ZZTat22-57 can confer on fNY-ESO-1 the ability to
induce B-lymphocytes to secrete IgG anti-fNY-ESO-1
antibodies. We incubated PBMCs in the presence or
absence of ZZTat22-57 or ZZfNY-ESO-1Tat22-57 and
cytokine/activator cocktail. Eleven days later, we collected
the SNs in order to examine by enzyme immunoassay the
presence of IgGs able to bind fNY-ESO-1-coated plates.
As shown in Fig. 5a, binding of SN from PBMCs incu-
bated with ZZfNY-ESO-1Tat22-57 and the cytokine/acti-
vator cocktail was significantly higher than binding of SN
from PBMCs incubated with ZZTat22-57 and the cyto-
kine/activator cocktails. We also assessed the number of
fNY-ESO-1-specific IgG-secreting B-lymphocytes by the
ELISPOT technique. We observed a very low number of
spots for control PBMCs incubated in the absence of Ag
and of the activating cocktail (Fig. 5b). We found a signifi-
cantly higher number of spots for PBMCs incubated with
IL-21/IL-4/anti-CD40. We assume that this corresponds
either to non-specific activation or to the presence of
B-lymphocytes secreting polyreactive IgGs since we
did not detect any anti-fNY-ESO-1 Ab by ELISA (see
Fig. 5a). We found a significantly higher number of
spots when cells were incubated with ZZTat22-57 and
IL-21/IL-4/anti-CD40, indicating that this mixture
stimulates B-lymphocytes able to secrete IgGs specific
to fNY-ESO-1.
Discussion
We previously showed that a specific IgM Ab response
is triggered by PBMCs incubated with a fusion protein
containing the transcriptional transactivator (Tat) of
HIV-1 and the ZZ double Ig-binding domain derived
from protein A of Staphylococcus aureus, suggesting that
this approach might represent a new strategy of in vitro
immunization [34]. Here, we addressed more thoroughly
the potential of this new strategy. As the absence of
anti-Tat IgGs indicated that ZZTat101 fails to induce the
isotypic switch, we first investigated whether we could
optimize our in vitro immunization procedure in order
to trigger an IgG Ab response. To this aim, we supple-
mented ZZTat101 and PBMCs with a mixture contain-
ing IL-4, IL-21 and CD40L or anti-CD40 since IL-4 and
IL-21 are reported to be switch factors when used in
combination with either CD40L or anti-CD40 [35, 36].
We did not detect a significant amount of anti-Tat IgG
in the supernatants resulting from the incubation with
the CD40L/IL-4/IL-21 mixture, indicating that it does
not provide an efficient switch. In contrast, we found a
significant amount of IgGs with anti-CD40/IL-4/IL-21.
Furthermore, Ab binding to Tat101-coated plates was
inhibited by soluble Tat101, while two soluble unrelated
antigens had little or no effect, indicating that this
humoral immune response is specific to Tat101. There-
fore, these results demonstrate that the anti-CD40/IL-4/
IL-21 mixture is of value in improving our ZZTat-based
in vitro immunization procedure and that the anti-CD40
Ab contributes more efficiently than CD40L to the iso-
type switch provided by IL-4 and IL-21. Moreover, and
interestingly, we did not find a significant increase in the
Fig. 4 An optimal anti-Tat specific B-lymphocyte response was reached
after 11 days of in vitro immunization. PBMCs were incubated for eight,
eleven or thirteen days in the presence or absence of anti-CD40/IL-4/IL-
21, ZZTat101 + anti-CD40/IL-4/IL-21, respectively. Then, PBMCs were
transferred from culture plates to ELISPOT plates previously coated with
Tat101. After an additional 24-h incubation at 37 °C, a biotinylated anti-
human IgG was added. Spot-forming cells were then detected using a
streptavidin-alkaline phosphatase conjugate and NBT/BCIP as substrate.
Spot-forming cells were quantified with an automated ELISPOT reader
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anti-Tat Ab response when we used a concentration of
ZZTat101 5-fold higher than that usually used (50 and
10 μg/mL, respectively), showing that it is not necessary
to increase Ag concentration in this in vitro
immunization procedure.
To decipher the molecular mechanisms underlying the
phenomenon of in vitro immunization, we assessed the
ability of a series of protein derivatives to trigger the
anti-Tat IgG Ab response when incubated with the anti-
CD40/IL-4/IL-21 mixture and PBMCs. We did not
detect anti-Tat IgGs with free ZZ, indicating that the
double IgG-binding domain cannot initiate the specific
humoral immune response. In addition, we observed that
free Tat101 and the noncovalent association of Tat101 and
ZZ are inefficient. Therefore, these results demonstrate that
Tat101 can stimulate the in vitro IgG Ab response only
when it is covalently coupled to ZZ. Furthermore, we did
not detect anti-Tat IgGs with the ZZTat101Ø molecule, in
which the basic residues of the basic-rich region of Tat have
been acetylated, which indicates that this basic-rich domain
is involved in the phenomenon. In contrast, the regions
1–21 and 58–101 of Tat are not crucial since the
ZZTat22-57 protein, which is devoid of these two regions,
triggers the humoral immune response in vitro. When we
used a ZZTat22-57 derivative in which the seven Tat cyste-
ines contained in the cysteine-rich region are replaced by
serines (ZZTat22-57C(22–37)S), we did not detect anti-Tat
IgGs, indicating that the cysteine-rich domain is involved in
the phenomenon. In our previous work done in the ab-
sence of the anti-CD40/IL-4/IL-21 mixture, we used the
same protein derivatives and reached the same conclusions
for the anti-Tat IgM Ab response [34]. Therefore, our ob-
servations strongly suggest that the in vitro anti-Tat IgM re-
sponse and IgG Ab response follow identical molecular
mechanisms of activation and that the anti-CD40/IL-4/IL-
21 mixture only provides the required signals to switch
from IgM to IgG.
We used an ELISPOT assay to determine the frequency
of B cell-producing Tat101-specific IgGs. With Tat101-
coated ELISPOT plates we detected SFCs when PBMCs
were incubated with the anti-CD40/IL-4/IL-21 mixture
only. This result contrasts with the absence of detection of
anti-Tat IgGs in the SNs resulting from the same incu-
bation during our ELISA experiments. As the anti-
CD40/IL-4/IL-21 mixture provides a strong polyclonal
B-cell activation, we speculate that this discrepancy
might be related to B-cell clones secreting IgGs with
low affinity for the ELISPOT Tat101-coated plates. We
counted significantly higher amounts of SFCs with
PBMCs incubated in the presence of anti-CD40/IL-4/
IL-21 and ZZTat101. Interestingly, we found a peak
ELISPOT response after 11 days of incubation, which
correlates with that found for the ELISA of the SNs
(not shown), indicating that the level of expansion of
Fig. 5 ZZTat101 is able to confer on fNY-ESO-1 the ability to induce
B-lymphocytes to secrete anti-fNY-ESO-1 IgG antibodies. a PBMCs
were incubated for eleven days without anti-CD40/IL-4/IL-21, with
ZZTat22-57 + anti-CD40/IL-4/IL-21 or ZZfNY-ESO-1Tat22-57 + anti-CD40/
IL-4/IL-21, respectively. Then, supernatants were collected and added to
anti-human IgG-coated plates. After an incubation of 2 h, biotinylated
f-NY-ESO-1 was added to each well. After overnight incubation, an
acetylcholinesterase-labeled streptavidin conjugate was added and
enzymatic activity was determined using Ellman's reagent. b PBMCs were
incubated for eleven days with or without anti-CD40/IL-4/IL-21, ZZfNY-
ESO-1Tat22-57 + anti-CD40/IL-4/IL-21, respectively. PBMCs were
transferred from culture plates to ELISPOT plates previously coated with
fNY-ESO-1. After an additional 24-h incubation at 37 °C, a biotinylated
anti-human IgG was added. Spot-forming cells were then detected using
a streptavidin-alkaline phosphatase conjugate and NBT/BCIP as substrate.
Spot-forming cells were quantified with an automated ELISPOT reader
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Tat101-specific IgG+ B-cells depends on the duration
of in vitro incubation.
To investigate whether our approach can be used to
confer on an unrelated non-haptenic peptide Ag the abil-
ity to trigger a specific IgG Ab response, we prepared the
ZZfNY-ESO-1Tat22-57 fusion protein containing a large
fragment derived from the NY-ESO-1 cancer/testis Ag.
When PBMCs were incubated with this fusion protein, we
detected a significant amount of anti-fNY-ESO-1 IgG in
the SN and the number of anti-fNY-ESO-1 SFCs was
significantly higher than that found for PBMCs incubated
with the anti-CD40/IL-4/IL-21 mixture alone.
Conclusions
Our data demonstrate that PBMCs become able to trigger
a human anti-Tat IgG Ab response when they are incubated
with anti-CD40, IL4, IL21 and different ZZTat derivatives.
Furthermore, they show that a NY-ESO-1 fragment raises a
specific IgG Ab response when it is coupled to ZZTat.
These results suggest that the ZZ-Tat based approach can
be used to raise an in vitro humoral immune response
against any Ag unrelated to Tat.
Methods
Antigens
Chemical synthesis of Tat101
Synthesis of Tat101 was performed as previously described,
using the Fmoc/tert-butyl strategy on an Applied Biosys-
tems 433A synthesizer [34]. After synthesis and completion
of the Cys deprotection, the mixture was purified by HPLC
on a C4 column and then characterized by mass spectrom-
etry and amino acid analysis.
Preparation of the fusion proteins
ZZ, ZZTat101, ZZTat22-57, ZZTat22-57C(22–37)S, the
acetylated ZZTat101 molecule called ZZTat101Ø and
ZZfNY-ESO-1Tat22-57 were produced using recombinant
technology as previously described [34]. Briefly, the genetic
fragments encoding the different sequences were inserted
into a pCP vector using SacI/KpnI/BamHI restriction sites
[40]. Then, E. coli BL21 (DE3pLysS) cells were transformed
with the plasmids encoding ZZTat101, ZZTat22-57,
ZZTat22-57C(22–37)S, ZZTat101Ø or ZZfNY-ESO-1Tat22-
57. Finally, the five protein constructs were expressed by
IPTG induction. Bacteria were mechanically lysed in the
presence of AEBSF protease inhibitor (Pefabloc, SIGMA).
The five ZZ-fusion proteins were purified by 20-min
incubation at 4 °C in NaCl (2 M) and protamine sulfate
(2 mg/mL) followed by a centrifugation to remove nucleic
acids. Then, the samples were dialyzed in PBS-Tween 20
(0.1 %) and loaded on an affinity column grafted with Abs
(IgG Sepharose 6 Fast flow #17-0969-02 Amersham).
Purification of human peripheral blood mononuclear cells
This study was performed in accordance with the
ethical standards of Declaration of Helsinki (http://
www.wma.net/en/30publications/10policies/b3/index.html).
Buffy coat samples from healthy blood donors, screened
negative for HIV-1/2, HTLV-I/II, HCV, HBsAg, were from
the Etablissement Français du Sang (EFS,Rungis, France).
They were collected from anonymous donors after signing
of an informed consent form and following Etablissement
Français du Sang guidelines. An agreement of transfer of
products stemming from blood or from its components
with no therapeutic purpose is signed between the CEA
and the EFS and renewed every year (number of conven-
tion: EFS: 13/EFS/101; CEA: CAJ-13-060-3). Peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll
Hypaque density gradient centrifugation (Histopaque 1077,
Sigma-Aldrich, St. Louis, MO). Plasma from donors was
isolated and stored at −20 °C for serological analysis. Cells
were washed in PBS (phosphate buffer saline: 10 mM
potassium phosphate pH 7.4 and 150 mM sodium chloride)
supplemented with 2 mM EDTA.
In vitro immunization
The in vitro immunization of PBMCs was performed in
96-well plates at 5 X 105 cells per well in a final volume
of 200 μL medium (RPMI-1640 supplemented with
2 mM L-glutamine, penicillin (50 IU/mL), streptomycin
(50 μg/mL), 50 μM β-mercaptoethanol and 10 % heat-
inactivated fetal bovine serum). The different cell popula-
tions were incubated in vitro in the presence or absence of
antigens (ZZTat101, ZZfNY-ESO-1Tat22-57, ZZ or Tat101,
ZZTat101 Ø, ZZTat22-57C(22–37)S and ZZTat22-57) at a
concentration of 10 μg/mL each and with or without an
activator cocktail containing different combination of
CD40L (1 μg/mL), anti-CD40 (1 μg/mL), IL4 (10 ng/
mL) and IL21 (50 ng/mL). After 8, 11 or 13 days of in-
cubation at 37 °C and 5 % CO2, culture supernatants
were collected, and the specific IgG content was mea-
sured using an enzyme immunoassay.
Detection of anti-Tat specific IgG using an enzyme
immunoassay
96-well microtiter plates (Maxisorp, Nunc, Roskilde,
Denmark) were coated with Tat101 (0.1 μg/well) in
50 mM sodium phosphate buffer (pH 7.4) at room
temperature overnight. Plates were washed once with
washing buffer (10 mM potassium phosphate buffer
pH 7.4 containing 0.05 % Tween 20) and saturated
with sodium phosphate buffer 100 mM containing
0.3 % bovine serum albumin (BSA) and 0.003 % Thy-
merosal and stored at 4 °C. Before use the plates were
washed three times with washing buffer.
For the assessment of the presence of anti-Tat IgG, a
fixed volume of supernatant was incubated in the
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presence or absence of a fixed amount (10 μg/mL) of dif-
ferent Ags (Tat101, ovalbumin, lysozyme) in microtiter
plates coated with Tat101. After overnight incubation at
4 °C, plates were washed three times and a peroxidase-
conjugated anti-human IgG (Jackson Immunoresearch
Laboratories) was added. After a 30-min incubation, plates
were washed and incubated with 2,2′-azinobis(3-ethyl-
benz-thiazoline-6-sulfonic acid) (ABTS). After 30 min of
incubation, absorbance was read at 414 nm.
Detection of anti-fNY-ESO-1 IgG using an enzyme
immunoassay
96-well microtiter plates (Maxisorp, Nunc, Roskilde,
Denmark) were coated with anti-human IgG (5 μg/well)
in 50 mM sodium phosphate buffer (pH 7.4) at room
temperature overnight. Plates were washed once with
washing buffer (10 mM potassium phosphate buffer
pH 7.4 containing 0.05 % Tween 20) and saturated with
enzyme immunoassay buffer (EIA) (100 mM phosphate
buffer pH 7.4 containing 150 mM NaCl, 0.1 % BSA and
0.01 % sodium azide) and stored at 4 °C. Before use the
plates were washed three times with washing buffer.
For the assessment of the presence of anti-fNY-ESO-1
IgG, a fixed volume of supernatant was dispensed into
the wells and reacted for two hours at room temperature.
The plates were then washed before the addition of
100 μL of biotinylated f-NY-ESO-1 to each well at a con-
centration of 30 ng/mL. After an overnight incubation at
4 °C followed by three washing cycles, 100 μL of acetyl-
cholinesterase (AChE; EC 3.1.1.7)-labeled streptavidin
conjugate (2 Ellman units (EU)/mL [41] was added to
each well. After 1 h of incubation at RT followed by three
washing cycles, 200 μL of Ellman's reagent [42] was added,
and the absorbance was measured at 414 nm.
Detection of specific Ab-forming cells by ELISPOT
Nitrocellulose-backed 96-well MAHAS4510 plates
(Millipore) were coated overnight at 4 °C with either
Tat or NY-ESO-1 (1 μg/mL each) in 50 mM sodium bi-
carbonate buffer (pH 9.6). Plates were washed and
blocked for 2 h at 37 °C with 10 % fetal calf serum in
RPMI. PBMCs were seeded at 3 X 105 cells/well and
incubated for 18 h at 37 °C. Spot-forming cells (SFCs)
were then detected using 1 μg/mL of biotinylated anti-
human IgG (Jackson Immunoresearch Laboratories) for
1.5 h at room temperature. Ab binding was evaluated
by the addition of streptavidin, alkaline phosphatase
conjugate and a chromogenic alkaline phosphatase sub-
strate (Pierce).
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